reaction
carbon
acid
water
reaction
allow
red
blood
cell
transport
carbon
dioxid
tissu
lung
elimin
red
blood
cell
contain
million
hemoglobin
molecul
molecul
hemoglobin
carri
four
heme
group
heme
group
bind
one
molecul
oxygen
four
separ
oxygen
molecul
bind
one
molecul
hemoglobin
gram
hemoglobin
carri
l
oxygen
formula
oxygen
deliveri
capac
blood
co
cao
oxygen
deliveri
co
cardiac
output
cao
oxygencarri
capac
blood
chang
volum
dl
ml
l
cardiac
output
co
recogn
co
hr
sv
hr
heart
rate
sv
stroke
volum
left
ventricl
cao
deriv
follow
way
hemoglobin
sao
pao
sao
percent
hemoglobin
satur
oxygen
arteri
circuit
coeffici
oxygen
solubl
blood
equat
illustr
pao
minim
part
oxygen
deliveri
sea
level
unless
hemoglobin
arteri
blood
satur
decreas
sever
purpos
erythrocyt
transfus
maintain
increas
oxygen
carri
capac
blood
almost
indic
transfus
hemoglobin
level
greater
gdl
almost
alway
indic
hemoglobin
less
gdl
preoper
hematocrit
estim
blood
volum
use
predict
transfus
requir
intraop
one
unit
pack
red
blood
cell
increas
hematocrit
approxim
hemoglobin
gdl
averag
adult
estim
total
blood
volum
cckg
blood
women
cckg
blood
men
estim
total
blood
volum
multipli
percent
hematocrit
give
estim
red
blood
cell
volum
estim
red
blood
cell
volum
hematocrit
previous
use
hematocrit
target
patient
cardiac
diseas
estim
total
blood
volum
multipli
subtract
estim
blood
volum
hematocrit
blood
volum
normal
hematocrit
give
volum
blood
patient
lose
reach
hematocrit
give
baselin
consid
blood
transfus
exampl
kg
man
kg
cckg
blood
volum
cc
blood
volum
hematocrit
blood
volum
erythrocyt
blood
volum
cc
multipli
yield
cc
erythrocyt
use
previous
target
hemoglobin
blood
volum
use
number
need
lose
cc
hematocrit
decreas
red
blood
cell
transfus
indic
symptomat
anem
patient
restor
oxygencarri
capac
deliveri
blood
viscos
determin
primarili
erythrocyt
concentr
anemia
blood
viscos
decreas
sever
turn
decreas
resist
blood
flow
peripher
blood
vessel
decreas
peripher
resist
return
larger
normal
quantiti
blood
tissu
heart
greatli
increas
cardiac
output
hypoxemia
also
result
decreas
transport
erythrocyt
decreas
peripher
vascular
resist
allow
blood
return
heart
increas
co
myocardi
oxygen
consumpt
anemia
decreas
oxygen
deliveri
also
increas
cardiac
output
myocardi
oxygen
consumpt
possibl
risk
end
organ
ischemia
lowest
limit
hemoglobin
toler
peopl
known
critic
limit
tissu
oxygen
remain
poorli
defin
even
detriment
effect
anemia
recent
trial
indic
transfus
necessarili
best
treatment
current
opinion
hold
univers
hemoglobin
hematocrit
transfus
trigger
inappropri
patient
situat
therefor
histor
transfus
trigger
hemoglobin
hematocrit
fallen
favor
intraop
postop
icu
patient
blood
loss
replac
crystalloid
colloid
solut
maintain
normovolemia
danger
anemia
outweigh
risk
transfus
patient
low
hemoglobin
level
surgeri
higher
risk
receiv
allogen
transfus
aborh
type
crossmatch
antibodi
screen
compat
test
test
design
demonstr
harm
antigenantibodi
interact
vitro
harm
vivo
interact
could
prevent
pretransfus
test
perform
ensur
abo
compat
donor
recipi
abo
group
remain
import
factor
test
like
caus
death
secondari
transfus
therapi
abo
incompat
three
common
allel
present
abo
locu
chromosom
abo
base
inherit
gene
encod
glycosyltransferas
add
specif
sugar
make
b
antigen
gene
codomin
individu
inherit
gene
design
ab
blood
type
homozyg
aa
heterozyg
ao
known
type
blood
inherit
creat
function
enzym
patient
make
antibodi
antigen
lack
type
peopl
lack
b
antigen
red
cell
antia
antib
antibodi
plasma
natur
occur
antibodi
occur
patient
even
prior
blood
exposur
antibodi
produc
abo
antigen
igm
capabl
caus
intravascular
hemolysi
incompat
blood
transfus
abo
test
sampl
whole
blood
centrifug
separ
red
cell
serum
process
allow
red
cell
serum
test
separ
allow
type
doublecheck
abo
group
determin
mix
patient
red
cell
use
antia
antib
reagent
reversetyp
patient
serum
b
reagent
cell
agglutin
occur
antia
reagent
patient
type
blood
agglutin
occur
antib
reagent
type
b
blood
caus
agglutin
type
ab
agglutin
type
blood
patient
serum
screen
presenc
unexpect
antibodi
incub
select
reagent
red
cell
screen
cell
use
antihuman
globulin
ahg
techniqu
indirect
antiglobulin
coomb
test
tabl
type
screen
test
look
aborh
type
screen
unexpect
antibodi
rh
system
red
blood
cell
rbc
antigen
c
e
c
e
signific
antigen
clinic
antigen
immunogen
rbc
antigen
known
rh
factor
antibodi
screen
consist
detect
abnorm
red
blood
cell
antibodi
clinic
signific
antigen
antigen
fraction
note
clinic
signific
antibodi
screen
neg
patient
past
histori
unexpect
antibodi
predict
abocompat
red
blood
cell
unit
would
compat
ahg
crossmatch
antibodi
screen
posit
approxim
patient
unexpect
antibodi
antibodi
must
identifi
antigen
negativecompat
rbc
found
process
usual
take
sever
hour
type
cross
includ
aborh
type
antibodi
screen
also
includ
mix
donor
red
blood
cell
recipi
serum
inspect
reaction
crossmatch
take
minut
character
three
phase
immedi
incub
antiglobulin
phase
two
import
phase
incub
antiglobulin
phase
antibodi
appear
phase
caus
sever
hemolyt
reaction
donor
blood
crossmatch
recipi
blood
blood
made
unavail
anyon
crossmatch
recipi
blood
bank
hour
emerg
blood
suppli
abo
type
least
antibodyinduc
type
blood
donor
blood
use
emerg
transfus
groupspecif
blood
must
screen
hemolyt
antia
antib
antibodi
rh
factor
neg
rh
factor
posit
blood
use
men
postmenopaus
women
small
risk
reaction
rh
factor
posit
blood
use
premenopaus
women
risk
transfus
rhposit
blood
rhneg
femal
caus
erythroblastosi
fetali
subsequ
pregnanc
tabl
summar
donor
blood
group
patient
may
safe
receiv
mani
complic
associ
blood
transfus
transfus
blood
shown
caus
immunomodul
system
inflammatori
respons
occlus
microvasculatur
increas
risk
postop
lowoutput
heart
failur
transfus
occur
coronari
arteri
bypass
surgeri
allogen
red
blood
cell
transfus
induc
immunomodul
recipi
transfus
allogen
donor
leukocyt
appear
mediat
signific
immunomodul
effect
leukocyt
deplet
may
reduc
immunomodul
immunomodul
caus
transfus
increas
incid
postop
infect
increas
risk
tumor
recurr
patient
resect
malign
doserespons
relationship
show
immunomodul
increas
increas
number
allogen
erythrocyt
transfus
administ
immunomodul
benefici
transplant
patient
allogen
blood
transfus
shown
improv
allograft
surviv
renal
transplant
mechan
immunomodul
suspect
caus
upregul
humor
immun
downregul
cell
mediat
immun
three
type
allerg
reaction
erythrocyt
transfus
mild
moder
anaphylaxi
transfus
reaction
note
transfus
stop
new
sampl
blood
sent
retyp
cross
mild
allerg
reaction
caus
focal
urticaria
occur
approxim
patient
character
wellcircumscrib
local
erythemat
rais
urticari
lesion
hive
associ
symptom
transfus
held
administ
antihistamin
resum
reaction
stop
moder
allerg
reaction
seen
clinic
widespread
skin
rash
respiratori
compon
includ
bronchospasm
stridor
transfus
stop
patient
may
requir
steroid
vasopressor
anaphylaxi
sever
system
allerg
reaction
medic
emerg
occur
blood
transfus
multipl
organ
system
involv
symptom
gener
begin
hive
dyspnea
flush
wheez
progress
cough
stridor
cardiovascular
collaps
transfus
must
stop
immedi
patient
treat
epinephrin
diphenhydramin
histamin
receptor
antagonist
steroid
intraven
fluid
febril
nonhemolyt
transfus
reaction
one
common
caus
temperatur
chang
blood
transfus
temperatur
must
chang
c
f
reaction
accompani
chill
anxieti
seen
often
patient
multipl
transfus
multipar
women
fever
detect
transfus
stop
patient
treat
antipyret
temperatur
begin
decreas
suspicion
septic
transfus
reaction
acut
hemolyt
transfus
reaction
elimin
transfus
may
start
bacteri
contamin
transfus
rbc
caus
sepsi
transfus
recipi
common
organ
associ
contamin
yersinia
enterocolitica
gramneg
organ
bacteri
contamin
rbc
unit
relat
directli
length
storag
contamin
gramneg
organ
result
occult
asymptomat
transient
donor
bacteremia
occur
collect
growth
cryophil
bacteria
yersinia
serratia
pseudomona
enhanc
refriger
storag
condit
rbc
endotoxin
produc
organ
also
induc
fulmin
sepsi
recipi
septic
transfus
reaction
caus
gramneg
rod
rapidli
fatal
mortal
rate
evolv
sever
hour
go
unrecogn
clinic
temperatur
increas
greater
c
sever
hypotens
hypertens
dissemin
intravascular
coagul
shock
seen
sign
symptom
may
absent
cold
surgic
patient
patient
postop
fever
symptom
occur
transfus
stop
sampl
blood
sent
cultur
patient
donor
unit
high
suspicion
treatment
initi
immedi
without
wait
cultur
broadspectrum
antibiot
treatment
shock
acut
renal
failur
arf
dissemin
intravascular
coagul
dic
initi
immedi
although
restrict
use
antibiot
particularli
broadspectrum
antibiot
import
limit
superinfect
decreas
develop
antibioticresist
pathogen
patient
sever
sepsi
warrant
empir
therapi
caus
organ
identifi
acut
hemolyt
transfus
reaction
frequent
caus
fatal
transfus
reaction
caus
abo
incompat
incid
per
transfus
half
death
acut
hemolyt
transfus
reaction
secondari
administr
error
sever
reaction
relat
amount
blood
transfus
acut
hemolyt
transfus
reaction
suspect
transfus
must
stop
untransfus
blood
return
blood
bank
along
sampl
patient
blood
retyp
crossmatch
support
care
ensu
transfusionrel
acut
lung
injuri
commonli
known
trali
acut
sever
respiratori
distress
syndrom
incid
per
unit
transfus
usual
occur
within
hour
transfus
character
acut
onset
dyspnea
hypoxemia
progress
noncardiogen
pulmonari
edema
requir
mechan
ventil
icu
treatment
pao
fio
ratio
less
spo
less
room
air
chest
radiograph
show
bilater
pulmonari
infiltr
donor
leukoagglutinin
donor
antibodi
human
leukocyt
antigen
hla
react
recipi
leukocyt
monocyt
hypothes
caus
trali
reaction
activ
complement
turn
lead
neutrophil
aggreg
increas
permeabl
pulmonari
microcircul
multipar
femal
donor
typic
carri
leukoagglutinin
treatment
trali
includ
support
measur
supplement
oxygen
tracheal
intub
mechan
ventil
posit
endexpiratori
pressur
peep
indic
reaction
usual
resolv
within
hour
patient
experi
complet
recoveri
case
resolv
within
day
transfus
high
incid
fatal
reaction
incid
pulmonari
edema
acut
respiratori
distress
syndrom
ard
higher
patient
transfus
liber
delay
transfus
reaction
consist
viral
contamin
delay
hemolyt
transfus
reaction
graft
versu
host
diseas
gvhd
viral
risk
includ
hiv
hepat
virus
b
c
hav
hbv
hcv
human
tcell
lymphotroph
viru
type
ii
new
virus
includ
hepat
g
viru
torqu
teno
tt
viru
human
herp
viru
associ
kaposi
sarcoma
hiv
transmiss
incid
hcv
incid
hbv
incid
along
multipl
virus
risk
transmiss
bacteria
parasit
malaria
date
malaria
chaga
diseas
sever
acut
respiratori
syndrom
variant
creuzfeldt
jakob
diseas
detect
screen
test
gvhd
rare
complic
result
foreign
lymphocyt
patient
die
gvhd
tlymphocyt
mediat
usual
occur
within
week
transfus
gbhd
target
host
endothelium
bone
marrow
result
aplast
anemia
pancytopenia
usual
seen
immunosuppress
patient
known
prevent
reaction
radiograph
gamma
radiat
donor
rbc
inactiv
donor
cell
hyperkalemia
hypocalcemia
acidbas
alter
commonli
note
metabol
complic
induc
blood
transfus
hyperkalemia
usual
seen
massiv
transfus
increas
red
cell
lysi
renal
failur
red
cell
store
leak
potassium
storag
fluid
leakag
correct
transfus
replenish
cell
energi
store
hypocalcemia
occur
citrat
bind
calcium
use
anticoagul
store
blood
product
rapidli
transfus
rbc
may
decreas
level
ioniz
calcium
recipi
liver
metabol
citrat
clinic
scenario
impair
liver
function
liver
transplant
hypothermia
citrat
metabol
may
decreas
ioniz
calcium
level
follow
total
serum
calcium
measur
citratebound
calcium
may
reflect
free
serum
calcium
accur
alter
acidbas
statu
occur
store
blood
becom
acid
secondari
accumul
rbc
metabolit
acid
load
minim
transfus
alkalosi
follow
massiv
transfus
common
secondari
metabol
citrat
bicarbon
liver
reason
seek
altern
allogen
blood
transfus
numer
includ
infecti
risk
short
suppli
rare
blood
phenotyp
massiv
transfus
set
patient
refus
allogen
blood
transfus
blood
conserv
strategi
includ
autolog
blood
transfus
acut
normovolem
hemodilut
intraop
blood
recycl
futur
option
may
includ
artifici
oxygen
carrier
sever
way
perform
autolog
blood
donat
techniqu
includ
acut
normovolem
hemodilut
preoper
blood
donat
intraop
blood
salvag
consid
periop
autolog
blood
donat
mandatori
care
select
patient
reduc
rate
discard
autolog
unit
autolog
blood
donat
one
simplest
econom
way
decreas
amount
allogen
blood
transfus
use
acut
normovolem
hemodilut
use
intraop
venou
drainag
one
unit
blood
intraop
storag
blood
blood
remov
replac
millilit
millilit
colloid
cc
crystalloid
cc
blood
remov
blood
replac
dextran
hetastarch
may
result
coagul
defect
crystalloid
colloid
volum
replac
also
decreas
risk
anaphylaxi
associ
dextran
volum
replac
allow
blood
lost
intraop
lower
hematocrit
idea
dilut
blood
may
lost
replac
concentr
blood
remov
begin
case
amount
blood
remov
hemodilut
calcul
use
formula
v
ebv
x
hihfhav
v
volum
blood
expect
remov
ebv
estim
blood
volum
tbw
kg
cckg
femal
cckg
male
hi
patient
initi
hematocrit
level
onset
hemodilut
hf
desir
hematocrit
end
hemodilut
hav
averag
hematocrit
level
hemodilut
hi
acut
normovolem
hemodilut
use
costeffect
procedur
expect
estim
blood
loss
greater
ml
less
expens
periop
autolog
blood
donat
elimin
risk
administr
error
may
occur
anytim
blood
bank
abil
patient
donat
suffici
blood
depend
total
blood
volum
abil
regener
red
blood
cell
autolog
blood
donat
someth
perform
patient
stabl
donat
elect
surgeri
known
requir
transfus
criteria
selfdon
outlin
american
associ
blood
bank
includ
donor
hemoglobin
greater
equal
gdl
hematocrit
age
weight
requir
amount
patient
donat
himherself
mlkg
bodi
weight
limit
includ
donat
least
hour
procedur
allow
patient
recov
intravascular
volum
statu
surgeri
allow
blood
bank
process
donat
blood
poor
candid
autolog
blood
donat
includ
patient
signific
heart
diseas
preoper
anemia
autolog
blood
donat
recommend
patient
undergo
procedur
incid
blood
transfus
low
contraind
autolog
blood
donat
includ
evid
infect
risk
bacteremia
surgeri
correct
aortic
stenosi
unstabl
angina
acut
seizur
disord
myocardi
ischemia
cerebrovascular
accid
within
month
donat
patient
cardiac
pulmonari
diseas
clear
surgeri
primari
physician
highgrad
left
main
coronari
arteri
diseas
cyanot
heart
diseas
uncontrol
hypertens
anoth
form
autolog
blood
donat
intraop
blood
salvag
cell
saver
includ
retriev
blood
surgic
patient
return
blood
patient
suction
devic
use
surgeon
aspir
shed
blood
anticoagul
citrat
heparin
return
dispos
steril
centrifug
bowl
collect
blood
wash
normal
salin
concentr
hemoglobin
return
second
bag
return
patient
cell
salvag
may
caus
metabol
acidosi
secondari
loss
bicarbon
associ
parallel
increas
chlorid
concentr
hyperchlorem
acidosi
red
blood
cell
recov
wash
normal
salin
calcium
magnesium
concentr
also
may
decreas
progress
cell
salvag
transfus
process
erythrocyt
suspens
never
administ
pressur
bag
contain
air
bag
place
pressur
risk
venou
air
embol
increas
greatli
caus
potenti
fatal
complic
wash
blood
sole
erythrocyt
may
contain
residu
heparin
patient
may
develop
coagulopathi
liter
transfus
salvag
cell
rbc
salvag
use
oper
nonsteril
field
oncolog
surgeri
base
risk
infus
bacteria
tumor
cell
patient
erythrocyt
product
regul
secret
erythropoietin
kidney
respons
renal
hypoxia
adequ
suppli
folat
iron
vitamin
erythropoietin
stimul
increas
red
cell
product
marrow
increas
oxygencarri
capac
exogen
erythropoietin
affect
erythropoiesi
way
elect
postsurg
patient
erythropoietin
stimul
rate
erythropoiesi
return
rbc
mass
steadi
state
exogen
erythropoietin
increas
rbc
mass
mani
anem
state
shown
preoper
surgic
patient
undergo
autolog
blood
transfus
demonstr
decreas
transfus
requir
postop
period
patient
given
erythropoietin
preoper
provid
iron
avail
also
given
anem
postop
patient
increas
rate
recoveri
normal
hemoglobin
level
periop
erythropoietin
expens
gener
well
toler
low
dose
cost
may
compar
preoper
autolog
blood
donat
option
increas
patient
red
cell
mass
surgeri
exogen
erythropoietin
efficaci
erythropoietin
reduc
volum
allogen
blood
transfus
per
patient
reduc
number
patient
requir
transfus
document
well
certain
popul
renal
insuffici
anemia
chronic
diseas
refus
transfus
combin
acut
normovolem
hemodilut
preoper
erythropoietin
found
effect
acut
normovolem
hemodilut
success
higher
hemoglobin
begin
hemodilut
use
recombin
human
erythropoietin
andor
iron
therapi
effect
increas
rbc
mass
preoper
current
research
focus
altern
blood
transfus
name
blood
substitut
blood
substitut
volumeexpand
oxygencarri
solut
two
type
blood
substitut
develop
hemoglobinbas
oxygen
carrier
perfluorocarbon
emuls
hemoglobinbas
oxygen
carrier
shown
promis
result
must
modifi
way
prolong
vascular
retent
decreas
renal
toxic
decreas
vasoconstrict
perfluorocarbon
emuls
increas
amount
oxygen
carri
blood
particul
natur
lead
advers
effect
includ
thrombocytopenia
influenzalik
symptom
elect
surgeri
replac
blood
loss
half
blood
volum
equival
five
unit
pack
red
blood
cell
restor
red
cell
mass
control
level
substanti
affect
hemostasi
patient
clot
function
platelet
count
clot
factor
assay
reach
abnorm
level
numer
studi
suggest
unit
blood
loss
replac
pack
rbc
crystalloid
solut
gradual
prolong
prothrombin
time
pt
partial
thromboplastin
time
ptt
detect
sign
microvascular
bleed
indic
onset
earli
coagulopathi
factor
assay
time
elect
case
somewher
around
one
blood
volum
lost
replac
reveal
signific
decreas
fibrinogen
may
contribut
gener
ooz
surgic
field
elect
case
signific
ongo
blood
loss
platelet
decreas
abnorm
level
rel
late
trauma
case
howev
thrombocytopenia
may
occur
rapidli
sometim
less
one
blood
volum
defect
primari
hemostasi
quantit
platelet
function
may
caus
earliest
microvascular
bleed
mainten
bodi
temperatur
fluid
warm
forc
air
heat
may
prevent
physiolog
depress
clot
factor
platelet
function
patient
lose
blood
threshold
eventu
reach
blood
compon
requir
addit
pack
red
cell
buffer
salt
solut
revers
trend
toward
coagulopathi
although
primari
focu
discuss
slow
blood
loss
elect
surgic
patient
note
onset
coagulopathi
occur
consist
earlier
trauma
patient
mani
case
show
laboratori
clinic
sign
ongo
coagulopathi
arriv
emerg
room
therefor
grow
prefer
trauma
care
favor
earli
prophylaxi
coagulopathi
first
unit
blood
given
emerg
patient
continu
blood
loss
heavi
blood
loss
whether
situat
elect
emerg
appear
easier
control
coagulopathi
earli
blood
compon
use
rather
regain
control
coagulopathi
present
blood
compon
use
massiv
transfus
situat
freshfrozen
plasma
ffp
platelet
cryoprecipit
recombin
factor
viia
prothrombin
complex
concentr
descend
order
frequenc
use
compon
indic
major
complic
method
monitor
hemostasi
essenti
knowledg
anesthesiologist
manag
bleed
patient
plasmafreshfrozen
plasma
freshthaw
plasma
plasma
remov
centrifug
unit
blood
frozen
later
use
contain
albumin
immun
globulin
clot
factor
retain
much
activ
thaw
transfus
hospit
larg
amount
plasma
use
unit
thaw
advanc
request
warm
thaw
plasma
readi
time
use
henc
use
term
freshthaw
rather
freshfrozen
center
indic
usag
ftp
ffp
ident
two
term
use
interchang
discuss
case
earli
coagulopathi
correct
transfus
ffp
usual
volum
cckg
citrat
ad
blood
donat
remov
plasma
prepar
adsol
pack
red
cell
transfus
plasma
rapidli
often
result
hypocalcemia
transient
hypotens
rapid
infus
ffp
consid
indic
small
bolu
dose
calcium
chlorid
mgkg
infus
slowli
antagon
citrat
plasma
slow
infus
plasma
affect
serum
calcium
ffp
provid
excel
colloid
volum
support
similar
albumin
abil
acut
support
intravascular
volum
contain
activ
clot
factor
fibrinogen
supplement
singl
unit
limit
fibrinogen
level
inadequ
cryoprecipit
would
prefer
ffp
correct
amount
freshthaw
plasma
ftp
requir
normal
prothrombin
time
patient
take
coumadin
may
produc
fluid
overload
patient
risk
congest
heart
failur
standard
ftp
therapi
situat
avoid
highrisk
patient
correct
emerg
manag
prothrombin
complex
concentr
labil
clot
factor
viii
ix
vwf
von
willebrand
factor
alreadi
may
decreas
plasma
process
freez
defici
factor
correct
specif
factor
concentr
mild
case
treat
desmopressin
noncellular
factor
ffp
also
may
respons
trali
report
follow
singleunit
ffp
transfus
rapid
exsanguin
trauma
ftp
may
indic
begin
fluid
resuscit
prophylaxi
therapi
coagulopathi
amount
ftp
recommend
rang
unit
ftp
everi
unit
pack
red
cell
evid
favor
higher
dose
base
comput
simul
studi
earli
ffp
therapi
support
report
observ
mani
trauma
unit
class
evid
support
random
clinic
trial
would
difficult
imposs
perform
emerg
set
murray
colleagu
note
rare
patient
coagulopathi
correct
ffp
usual
would
microvascular
bleed
control
infus
platelet
platelet
concentr
target
mm
usual
consid
threshold
thrombocytopenia
associ
quantit
defici
primari
hemostasi
patient
ongo
blood
loss
requir
replac
blood
compon
lower
threshold
coagulopathi
half
level
gener
consid
appropri
patient
stabl
blood
volum
assum
maintain
equilibrium
platelet
consumpt
releas
reservoir
reticuloendotheli
system
platelet
suppli
either
pool
pack
separ
five
six
unit
whole
blood
process
apheresi
unit
singl
donor
platelet
pack
either
sourc
increas
platelet
count
nonbleed
nonconsum
patient
thrombocytopenia
result
dilut
consumpt
clinic
practic
treatment
usual
dissemin
intravascular
coagul
suspect
howev
determin
treatment
incit
caus
major
focu
therapi
platelet
sepsi
trali
two
lead
caus
death
blood
compon
therapi
last
decad
although
incid
plateletrel
sepsi
low
bacteri
growth
platelet
pack
storag
room
temperatur
mortal
risk
signific
trali
platelet
sepsi
account
death
per
year
unit
state
mortal
incompat
blood
transfus
cryoprecipit
fraction
cool
thaw
plasma
given
pool
unit
separ
donor
thaw
prepar
patient
blood
bank
may
delay
prepar
cryoprecipit
rel
expens
must
given
immedi
receiv
expir
hour
prepar
addit
larg
amount
fibrinogen
pool
signific
factor
viii
xiii
von
willebrand
factor
preserv
process
activ
infus
cryoprecipit
best
replac
fibrinogen
defici
complic
moderatetosever
blood
loss
includ
massiv
transfus
protocol
recombin
factor
viia
recombin
fviia
novoseven
novo
nordisk
pharmaceut
princeton
new
jersey
work
sever
point
coagul
cascad
produc
thrombin
burst
promot
coagul
replac
endogen
fvii
earliest
clot
factor
affect
dilut
vivo
also
decreas
rapidli
vitro
storag
blood
plasma
expens
price
mg
dose
use
novoseven
trauma
offlabel
factor
approv
use
hemophilia
b
fviii
fix
inhibitor
procoagul
activ
novoseven
inhibit
acidosi
hypothermia
requir
adequ
amount
substrat
function
properli
prothrombin
clot
factor
must
present
slow
control
coagulopath
bleed
load
ffp
possibl
cryoprecipit
encourag
use
provid
adequ
procoagul
concentr
circul
enthusiasm
procoagul
action
decreas
recent
report
possibl
thrombot
complic
report
press
current
document
medic
literatur
peerreview
public
result
anecdot
experi
sever
trauma
center
militari
experi
iraq
use
novoseven
initi
care
bleed
trauma
patient
advoc
quit
recent
stop
mani
trauma
center
restrict
lower
dose
mg
dose
use
treat
coagulopathi
novoseven
promot
thrombot
complic
whether
dose
restrict
prevent
problem
proven
retrospect
review
clinic
experi
sever
medic
center
includ
author
confirm
thrombot
complic
patient
receiv
fviia
although
admittedli
care
conduct
prospect
studi
potenti
thrombot
event
follow
novoseven
therapi
either
confirm
reject
expens
therapi
question
dose
rang
author
continu
use
high
dose
massiv
transfus
protocol
lack
local
evid
substanti
complic
associ
use
new
clot
factor
prepar
deriv
pool
plasma
includ
concentr
factor
ii
factor
vii
factor
ix
factor
x
lipidsolubl
factor
decreas
anticoagul
coumadin
use
revers
coumadin
effect
correct
prothrombin
time
normal
clinic
situat
rapid
revers
coumadin
need
emerg
surgeri
intern
bleed
patient
take
coumadin
requir
rapid
control
prothrombin
complex
concentr
pcc
recent
suppli
transfus
medicin
servic
experi
limit
earli
indic
occasion
may
revers
coumadin
inadequ
content
factor
vii
may
reduc
process
prothrombin
time
return
normal
follow
use
half
dose
fviia
mg
may
administ
intraven
boost
inadequ
fvii
activ
pcc
ravind
sarod
md
person
commun
tendenc
toward
arteri
thrombosi
small
percentag
patient
less
note
follow
pcc
center
studi
prospect
welldesign
seri
probabl
prepar
new
wide
use
center
time
defin
american
associ
blood
bank
massiv
transfus
replac
one
blood
volum
unit
blood
period
onehalf
blood
volum
five
unit
blood
period
hospit
busi
trauma
servic
treat
injur
patient
whose
transfus
need
exceed
limit
almost
daili
basi
addit
occasion
elect
surgeri
patient
coagulopathi
also
meet
simpl
criteria
patient
need
massiv
transfus
support
blunt
penetr
trauma
alreadi
rapidli
exsanguin
injuri
arriv
emerg
room
patient
hypovolem
hypotens
arriv
usual
receiv
larg
volum
crystalloid
balanc
salt
solut
initi
stabil
transport
may
need
transfus
immedi
decis
immedi
transfus
volum
replac
pack
red
cell
base
assess
vital
sign
acidbas
statu
reflect
arteri
blood
ga
determin
blood
loss
may
result
anemia
coagul
abnorm
specif
coagul
assay
even
perform
bedsid
may
take
long
perform
reflect
rapidli
chang
condit
trauma
patient
test
serv
confirm
effect
ongo
therapi
rather
guid
futur
therapi
acut
situat
coagul
factor
therapi
therefor
base
empir
assumpt
relat
estim
blood
volum
loss
circumst
trauma
servic
north
america
europ
set
massiv
transfus
protocol
design
support
rapid
transfus
regular
shipment
blood
product
releas
automat
time
basi
product
organ
fiveunit
increment
pack
red
cell
vari
blood
product
typic
need
level
blood
loss
trigger
request
anesthesiologist
surgeon
blood
shipment
would
continu
uninterrupt
protocol
bleed
control
patient
expir
massiv
transfus
protocol
mtp
parkland
memori
hospit
oper
year
fig
first
unit
blood
loss
primari
need
volum
support
pack
rbc
crystalloid
level
specif
clot
factor
maintain
ftp
usual
given
support
blood
volum
attempt
control
coagulopathi
earli
phase
unit
blood
loss
platelet
level
fibrinogen
level
decreas
rapidli
replac
platelet
pack
cryoprecipit
may
necessari
support
coagul
roughli
one
blood
volum
blood
loss
factor
vii
procoagul
may
reach
margin
level
earli
use
highdos
novoseven
mg
includ
protocol
time
earli
experi
protocol
shown
blood
product
provid
maximum
rate
unit
pack
red
blood
cell
prbc
per
hour
variou
compon
given
schedul
circumst
possibl
maintain
blood
volum
arteri
pressur
satisfactorili
use
blood
product
deliv
automat
accord
schedul
patient
protocol
maintain
clot
function
near
normal
valu
transfer
icu
patient
surviv
seem
improv
use
protocol
group
consecut
patient
meet
mtp
criteria
prior
begin
protocol
treat
blood
product
direct
anesthesiologist
trauma
surgeon
patient
surviv
day
first
two
year
protocol
surviv
year
remain
rang
better
control
group
amount
prbc
unit
transfus
marker
number
blood
shipment
sent
protocol
appear
reduc
compar
total
prbc
unit
use
control
group
would
appear
patient
clot
better
bleed
less
assum
homogen
trauma
popul
past
year
novoseven
introduc
wider
clinic
use
control
group
studi
howev
reduct
total
blood
product
might
due
partli
sole
use
rfviia
rather
greater
use
procoagul
schedul
mtp
number
patient
mtp
year
roughli
size
control
group
around
ongo
analysi
variabl
within
survivor
nonsurvivor
group
may
yield
inform
ravind
sarod
md
person
commun
januari
implement
mtp
produc
gener
improv
deliveri
blood
product
oper
room
trauma
resuscit
reliev
anesthesia
nurs
personnel
continu
worri
blood
suppli
urgent
trauma
surgeri
great
benefit
opinion
involv
staff
outcom
data
prove
mtp
benefit
patient
difficult
produc
benefit
term
better
clot
function
improv
surviv
may
sever
year
away
save
blood
product
could
cite
advantag
data
analysi
suggest
roughli
decreas
blood
product
usag
massiv
transfus
use
protocol
actual
persist
futur
data
appear
mtp
proven
worth
conveni
medic
nurs
personnel
even
patient
benefit
cost
save
entir
proven
benefit
time
